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Abstract
Cancer of unknown primary (CUP) is an obscure disease charac-
terized by multiple metastases in the absence of a primary
tumor. No consensus has been reached whether CUPs are
simply generated from cancers that cannot be detected or
whether they are the manifestation of a still unknown nosolog-
ical entity. Here, we report the complete expression and
genetic analysis of multiple synchronous metastases harvested
at warm autopsy of a patient with CUP. The expression profiles
were remarkably similar and astonishingly singular. The whole
exome analysis yielded a high number of mutations present in
all metastases (fully shared), additional mutations (partially
shared) accumulated one after another in a series, and few
private mutations were unique to each metastasis. Surprisingly,
the phylogenetic trajectory linking CUP metastases was atypi-
cal, depicting a common “stream”, sprouting a series of linear
“brooks”, at variance from the extensive branched evolution
observed in metastases from most cancers of known origin. The
distinctive genetic and evolutionary features depicted suggest
that CUP is a novel nosological entity.
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Introduction
In spite of representing 3–5% of all new cancer diagnoses, cancer of
unknown primary (CUP) is the fourth most common cause of
cancer-related deaths worldwide (Pavlidis & Pentheroudakis, 2012;
Varadhachary & Raber, 2014) and remains a mysterious nosological
entity sharing common traits: (i) early dissemination; (ii) unpre-
dictable organ distribution; (iii) lack of tissue-specific differentiation
markers; and (iv) poor prognosis. The elusive CUP biology results
in the lack of effective, pathogenesis-based therapy (Golfinopoulos
et al, 2009). The standard of care for CUPs is based on chemother-
apy, driven by an empirical, semi-agnostic, approach based on
histological suggestions from a panel of immunohistochemical
markers (Fizazi et al, 2015).
Until recently, major efforts have been directed to predict the
tissue of origin by means of immunohistochemistry (Greco et al,
2012), gene expression (Hainsworth et al, 2013), miRNA (Søkilde
et al, 2014), or epigenetic (Moran et al, 2016) profiling, with the
assumption that the knowledge of the putative tissue of origin could
dictate therapeutic strategies. Yet, a recently published clinical trial
showed no advantages of a molecularly defined, site-specific
chemotherapy regimen compared with an empirically chosen
chemotherapy (Hayashi et al, 2019). Another approach, which
awaits confirmation, consists of finding druggable molecular target
(s) (Ross et al, 2014). Thus, mutational profiles could be useful to
reveal CUPs’ vulnerabilities (the “precision medicine” approach).
Genomic surveys of CUPs, performed on panels of selected cancer
genes, have been recently presented (Ross et al, 2014; Löffler et al,
2016; Varghese et al, 2017; Zehir et al, 2017), but a distinguishable
and specific genetic signature has not emerged and no actionable
targets have been identified. Moreover, the typical multimetastatic
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presentation of CUPs might represent a further major challenge for
precision medicine since the genetic makeup of each metastasis
might be rather heterogeneous, undermining the outcome of thera-
pies tailored on genetic alterations detected in the single lesion
subjected to biopsy.
On the theoretical ground, it remains an open question whether
CUPs are a jumble of metastatic cancers where the primary cannot
be detected, or they are a still unrecognized cancer type propelled
by distinctive genetic and molecular features (Pentheroudakis et al,
2007). To answer, we tried to decipher the evolutionary trajectories
linking the multiple and synchronous metastases arising in a patient
with CUP, thus providing genetic evidence for a new nosological
entity and hints to envisage targeted therapeutic interventions.
Results
A thorough diagnosis of CUP
We studied in depth a 49-year-old male presenting with rapidly
progressing multiple metastases in different sites. A thorough multi-
step workout was conducted following the ESMO guidelines, which
excluded the presence of a primary tumor (Fizazi et al, 2015)
(Fig 1A–D and Table EV1). Histology of an ultrasound-guided core
biopsy of a breast metastasis revealed a poorly differentiated tumor
with adenocarcinoma features (Fig EV1). The tumor was intensively
immunoreactive for cytokeratins 7, AE1/AE3, and BCA225, and
focally positive for cytokeratin 20, whereas it was negative for the
markers listed in Table EV1 (Fig EV1). Cancer-associated genetic
alterations scrutinized by OncoCartaTM were undetectable
(Table EV2). The patient was offered a treatment in a phase 2 trial,
assessing nab-paclitaxel-based doublet as first-line therapy in CUPs
(AGNOSTOS trial, no. 008-IRCC-10IIS-14). Nevertheless, he
progressed rapidly and after two cycles he was withdrawn from
chemotherapy. Three months later the patient succumbed and
underwent a “warm” autopsy. Fifteen spatially distinct metastases
encompassing eight different organs/tissues were harvested: left
axillary lymph node (n = 1), abdominal subcutis (n = 1), right colic
flexure (n = 1), liver (n = 4), kidney (n = 2), gluteal subcutis
(n = 1), mediastinum (n = 1), right-side breast (n = 1), and lung
(n = 3). All investigated sites showed the same histology (Fig 1D),
superimposable to the diagnostic breast biopsy (Fig EV1).
Cancer of unknown primary diagnosis was further confirmed at
the transcriptional level. RNA-seq analysis of metastases from six
sites (right colic flexure, liver, kidney, mediastinum, breast, and
lung) yielded gene expression profiles that were similar among each
other but did not match the profiles available in the TCGA dataset
of any conventional primary tumor (i.e., tumors originated in a
recognizable organ) or metastases from known primaries (Fig 2).
Two primary ovarian cancers used as controls displayed expression
profiles similar to that of ovarian cancers deposited in the TCGA
dataset. The hierarchical clustering analysis, based on correlation
distance, was performed starting from the median expression pro-
files of each primary cancer type or metastases calculated from data
deposited in TCGA. All median expression profiles preserve the
tissue-specific identity feature (i.e., each metastasis clusters close to
its tumor of origin; Fig EV2B). The transcriptional profiles of CUP
metastases were unrelated to any putative tissue of origin (unlike
metastases originated from known primaries) and enlightened a
distinct expression signature.
Genomic characterization
The genomic DNA extracted from the fifteen metastases was
analyzed by whole exome sequencing (WES) and compared with
the patient’s own peripheral blood mononuclear cell DNA. The
average depth of coverage was about 100× (Fig EV3). Single nucleo-
tide variants (SNVs) and small insertions and deletions (InDels)
were called with Strelka2 (Kim et al, 2018) to identify somatic alter-
ations (Dataset EV1).
The presence of germline mutations in the eight genes responsi-
ble for the main hereditary human tumors (BRCA1, BRCA2, CDH1,
CTNN1A, MLH1, MSH2, MSH6, and p53), suspected because of the
patient’s familial history of multiple cancers, was excluded.
In the fifteen CUP metastases, the genetic analysis yielded a
number of nonsynonymous SNVs/InDels ranging from 144 to 376
(Fig 3A) for a total of 748 unique changes. Mutation rate varied
from 6.00 to 8.00 mutations per 106 bases, thus excluding that any
metastases were hyper-mutated (Network, 2012). The predominant
signature of C>A transversions observed was consistent with a
smoking signature (Alexandrov et al, 2016). All samples were
microsatellite stable (Boland & Goel, 2010).
The mutations identified were classified as (i) fully shared, (ii)
partially shared, or (iii) private. (i) We considered fully shared the
mutations displayed by at least 80% of metastases (i.e., 12/15). This
threshold was chosen since differences in coverage, at any given
region, would potentially produce false positives (i.e., mutations
present only in one or few metastases) or false negatives (i.e., the
absence of a mutation in one or more samples, due to insufficient
coverage). By these criteria, 276 mutations were fully shared. (ii)
On top of this common mutational pattern, additional mutations
accumulated incrementally in each metastasis. These mutations,
added one after the other in different metastases, were defined as
partially shared. (iii) Finally, a few private mutations (from 4 to 48)
were unique to each metastasis (Fig 3A). Indeed, the genetic concor-
dance of the fifteen metastases, measured as a function of Jaccard
similarity, ascertains a low degree of inter-metastases heterogeneity
as all metastasis (but lesion L_8) display a similarity ranging from
58 to 82% (Figs 3B and EV4). The exception of L_08 is due to the
scarce number of mutations displayed; nevertheless, out of the 144
somatic SNVs observed, four were partially shared and only four
private. All remaining mutations were fully shared with other
metastases.
The clonal composition of the fifteen metastases, performed by
clustering the variant allele frequency according to the algorithms
SciClone (Miller et al, 2014) and ClonEvol (Dang et al, 2017), varied
from 1 to 8, mostly following a linear pattern of evolution (Fig 3C).
Clones harboring the same mutations expanded at different rates in
different metastases (Fig 3D).
Although identification of the genes involved in CUP onset and
progression is not the focus of this analysis, it is worth to mention a
few mutations occurring in known tumor-associated genes. In fact,
within the 276 fully shared mutations (Dataset EV1), we found
genetic lesions in the oncogene NTRK1 and the tumor suppressors
TP53, ARID2, SMARCA4, ZFHX3, all of which have been described
in CUPs (Zehir et al, 2017).
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Figure 1. CUP diagnosis.
A Multistep ad excludendum diagnostic workflow: diagnosis performed in accordance with ESMO guidelines (Fizazi et al, 2015), starting from clinical evaluation and
proceeding with the sequential examinations represented in clockwise order. &Serum and immunohistochemistry markers are listed in Table EV1. $Cancer-
associated genes are listed in Table EV2. GI: gastrointestinal.
B, C Metastases distribution: The fifteen metastases were retrieved at warm autopsy from 8 tissues/organs. Samples are numbered according to the sequence of harvest
at autopsy.
D Histology: All metastatic lesions are composed of poorly differentiated cells with an epithelial “flavor”. The neoplastic population is mainly arranged in solid nests
and sheets with focal rudimental gland formation. Scale bar: 50 lm.
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Phylogenetic tree reconstruction
Exploiting the whole exome analysis of the multiple metastases
harvested from the same patient, and taking into account both
synonymous and nonsynonymous mutations (SNVs and InDels)
occurring in each metastasis and their purity-corrected frequencies
(Phylip tool; Felsenstein, 2005), we reconstructed the phylogenetic
relationships. While previous studies on metastases disseminated
by known primary tumors revealed branched patterns mostly
modeled as trees (Gerlinger et al, 2012) or stars (Sottoriva et al,
2015), analysis of the patient with CUP identified a single common
“stream”, sprouting a series of sequential linear “brooks”. Figure 3E
shows the sequential alignment of the fifteen metastases, based on
the phylogenetic tree inferred by Phylip implemented by private
mutations observed in each metastasis (Fig EV5). This picture
suggests an unusual phylogenetic evolution consistent with the exis-
tence of a common ancestor that continues to accumulate mutations
in a linear fashion, releasing over time collateral branches (the dif-
ferent metastases), each of which accrues an independent smaller
mutational burden. The common ancestor is obviously undetectable
in the patient body and may not necessarily display the features of a
conventional cancer stem cell that generates a primary tumor mass.
Rather, this ancestor might release in the bud its evolving progeny,
which would rapidly disseminate and form metastases in tissues
where microenvironmental conditions favor settlement and local
growth.
Discussion
The conventional approach to therapy of cancers of unknown
primary relies in pushing the molecular characterization of the
metastatic lesions to the limits, to bet on a putative tissue of origin,
and to treat the patients as if they were affected by a highly meta-
static cancer of that tissue (Hayashi et al, 2019). It is possible that
by this approach more (or possibly all) currently defined CUPs will
be re-classified in a “tissue-gnostic” way. As an alternative, CUPs
might turn out to be a nosological entity with distinctive traits. Iden-
tification of the gene(s) and the molecules responsible for these
traits could provide hints to understand the biology of early tumor
dissemination, from one side, and to pinpoint new selective thera-
peutic targets from the other. We approached the problem by a
comprehensive comparative analysis of the transcriptional profiles,
the genetic traits, and the phylogenetic relationship among multiple
synchronous and spatially distinct metastases in an exemplary case
of CUP. Such information has never been reported.
The first surprise was the expression profiles shared by CUP
metastases which were, otherwise, dissimilar from the profiles
displayed by the plethora of normal and tumor cells (including
metastases) deposited in the TCGA dataset.
The second unexpected finding was the high degree of similarity
among the mutational makeup of different CUP metastases, unlike
what commonly observed among metastases from tumors of known
origin (Gerlinger et al, 2012; Sottoriva et al, 2015). This similarity is
surprising since the precocious dissemination of the disease would
suggest high inter-metastases heterogeneity according to the parallel
progression model (Naxerova & Jain, 2015). Indeed, when metas-
tases from known primary tumors disseminate early, they continue
to evolve independently, giving rise to a wide genetic divergence.
However, the high degree of homogeneity among CUP metastases is
consistent with the rapid clinical evolution: after homing into multi-
ple tissues, founder cells generate metastases leading patients to
death in such short a time that only minimal divergent evolution
can take place.
The incremental accumulation of “partially shared” and the
presence of few “private” mutations in individual metastases
allowed drawing the phylogenetic tree. The inferred evolutionary
pattern is unusual in metastases originated from known primary
tumors. As described, the phylogenetic trajectory depicted a
“stream-like” path from which a number of linear “brooks” origi-
nated. This pattern is surprisingly reminiscent of the expansion of
a galaxy (Fig EV5). An alternative botanical metaphor recalls the
olive tree terminal shoot.
This model is consistent with the presence of a common cell of
origin with stem-like features that after accumulating the common
set of mutations, including all those affecting the putative driver
genes, became fully malignant, and acquired the ability to relent-
lessly proliferate and disseminate its progeny. Such progeny likely
underwent further accrual of the “partially shared” mutations and
modest divergence, in the meantime spreading across the organism.
At different metastatic sites, the founder cell(s) generated metas-
tases where the accumulation of “private” mutations was minimal.
Although the identification of possible metastatic drivers is
beyond the scope of the paper, the mutational analysis enlightened
a few candidate genes—shared by all metastases—and many possi-
ble gene combinations that may interfere with key signaling path-
ways controlling invasive growth (Comoglio et al, 2018). Among
the mutations conserved in all metastatic sites, it is worth mention-
ing truncation of TP53, and critical amino acid substitutions in the
transcription factor ZFHX3, in the receptor NTRK1, and in the chro-
matin remodeling proteins ARID2 and SMARCA4, already suspected
to be implicated in CUP pathogenesis (Zehir et al, 2017).
◀ Figure 2. Hierarchical clustering analysis of gene expression profiles of six CUP metastases.Triplicate samples of L_03, L_04A, L_07A, L_09, L_10, and L_12C are compared with the expression profiles deposited in the TCGA dataset of a spectrum of primary tumors or
metastases (meta) from known origin. Two ovarian cancers analyzed in house (CTR_OV1 and CTR_OV2) were used as controls and have expression profiles matching the
profiles displayed by the ovarian cancers listed in TCGA (purple box). The acronyms are as follow: ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA,
breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC,
lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH,
kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma;
LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma;
PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM,
skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus
endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
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Data gathered in this paradigmatic patient suggest that cancers of
unknown primary behave as a distinct nosological entity. Although
collection of multiple samples from a single patient is not trivial,
further accrual of cases is required to strength the hypothesis. On
the clinical ground, the unexpected genetic similarity among dif-
ferent CUP metastases leaves room for a therapeutic strategy aimed
at the simultaneous eradication of multiple lesions.
Materials and methods
Patient recruitment, diagnosis, and tissue collection
Patient was enrolled at Candiolo Cancer Institute within AGNOSTOS
Trial (no. 008-IRCC-10IIS-14) approved by the Institute Ethical
Committee. Informed consensus was obtained from patient, and the
experiments were conformed to the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report. CUP diagnosis was made following the ad
excludendum diagnostic workflow in accordance with ESMO guide-
lines (Fizazi et al, 2015). Fresh human specimens were collected
during a “warm” autopsy and either stored in RNAlater (Life Tech-
nologies) or fixed in 4% buffered formaldehyde and embedded in
paraffin.
Immunohistochemistry and fluorescence in situ hybridization
Sections were either stained with hematoxylin and eosin or collected
on Superfrost plus slides and used for immunohistochemistry (IHC)
and fluorescence in situ hybridization (FISH) analyses. IHC was
performed using the antibodies listed in Table EV3 and revealed
with Liquid DAB + Substrate Chromogen System (K3468; Dako)
using Ventana Benchmark ultra System (Roche), Bond Max (Leica
Biosystems), or Autostainer Link 46 (Agilent). FISH was carried out
using the Histology FISH Accessory kit (DAKO) and the probes
listed in Table EV3. Images were acquired using an Olympus BX61
microscope (Olympus Corporation) and analyzed using CytoVison
software (Leica Biosystems).
RNA extraction, libraries preparation, and sequencing
Samples were macrodissected to select tumor cells before RNA
extraction; after macrodissection percent of tumor cells—assessed
independently by two pathologists—was above 70% in every single
specimen. Total RNA was extracted from three different regions of
each metastases retrieved at warm autopsy and stored in RNAlater
solution by Maxwell RSC Instrument (Promega) using Maxwell
RSC miRNA Tissue Kit (Promega). Quantification was performed on
a Bioanalyzer 2100 (Agilent) using RNA 6000 nano Kit (Agilent).
RNA-seq analysis was performed on six metastases (right colic
flexure, liver, kidney, mediastinum, breast, and lung), and the
choice was dictated by quality controls. Libraries were prepared
with Illumina TruSeq Stranded mRNA kit starting from 600 ng of
total RNA, and samples were fragmented and amplified for 15 PCR
cycles. Libraries were size selected with Blue Pippin (Sage Science)
using 1.5% gel cassettes and 350–550 bp regions isolated. Sequenc-
ing was performed in 75 paired ends with NextSeq 500 (Illumina)
using NextSeq 500/550 High Output kit v2 (150 cycles).
Sequence alignment and expression profiles
Each FASTQ file was aligned using HISAT v. 2.1.0 (Kim et al,
2015) using hg19 as genome reference. Transcripts assembly was
performed with StringTie v. 1.3.33 and quantification performed
using gffcompare v. 0.10.1 (https://ccb.jhu.edu/software/stringtie/
gffcompare.shtml). The estimated abundance for the transcripts
was expressed as FPKM values (Fragments Per Kilobase of tran-
script per Million mapped reads) (Pertea et al, 2016). The data
were transformed into gene-level quantification by summing the
FPKM of the transcripts associated with the same gene and trans-
formed into log2(FPKM + 1). To compare the expression profiles
of eight CUP samples and two controls (ovarian cancers) with
those deposited in the TCGA dataset, a median expression profile
of 33 tumor types was created. TCGA expression data profiles
were retrieved as FPKM using the TCGAbiolinks package (Cola-
prico et al, 2016). The analysis was limited to samples labeled as
“Primary Solid Tumor”, “Primary Blood Derived Cancer—Periph-
eral Blood”, or “Primary Blood Derived Cancer—Bone Marrow”.
For each gene and each of the 33 tumor types, we extracted the
median FPKM across all samples to generate the median expres-
sion profile of each tumor type and the profiles transformed into
log2(FPKM + 1). TCGA transcriptional profiles were normalized
together using the normalize quantiles function of preprocessCore
package in the R statistical environment v3.6 (Fig EV2A). Cluster-
ing analysis was performed using hclust function of R statistical
environment v3.6 and ward.D2 as agglomeration method. The
◀ Figure 3. Genetic analysis of fifteen CUP metastases.A Somatic mutations distribution: SNVs and InDels displayed by each metastasis (listed in the y-axis) were detected by Strelka2 tool (Kim et al, 2018). Brown traits
represent single mutations. The number of fully shared (red), partially shared (orange), or private (yellow) mutations is indicated in the horizontal bar below. Five
cancer-associated genes (TP53, ARID2, NTRK1, SMARCA4, and ZFHX3) mutated in all metastases are highlighted.
B Genetic similarity among metastases: the heatmap has been drawn according to the Jaccard index. The similarity ranges from 58 to 82% among all pairs with the
exception of L_08 due to the scarce number of mutations.
C Clonal composition analysis: representative nested view of metastasis L_01. The five sub-clones (represented in different colors) inferred by clustering similarities of
the variant allele frequencies (VAFs) follow a linear pattern.
D Variant allele frequency of fully shared mutations present in copy neutral regions. The box plot represents the fluctuation of the VAF (in the y-axis) of single
mutations (grey dots) in each metastasis; each box represents the upper and lower quartiles, while the central short black line within each box represents the
median; whiskers indicate variability outside the upper and lower quartiles.
E Reconstruction of the phylogenetic tree linking the fifteen CUP metastases: the model was reconstructed by taking into account the maximum likelihood molecular
evolutionary tree according to Phylip (Felsenstein, 2005) and the incremental number of mutations. “Brooks” lengths are proportional to the amount of “private”
mutations.
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distances among transcriptional profiles were computed as one
minus the person correlation coefficient while clusters were iden-
tified using dynamicTreeCup package (Langfelder et al, 2008) in
the R statistical environment v3.6.
gDNA extraction, library preparation, and sequencing
gDNA was isolated using Relia PrepTM gDNA Tissue Miniprep
System (Promega). Normal gDNA was derived from peripheral
blood mononuclear cells (PBMCs) of the same patient using Relia-
PrepTM Blood gDNA Miniprep System (Promega). DNA was quanti-
fied using Nanodrop ND1000 spectrophotometer (Thermo Fisher
Scientific) and Qubit 4 Fluorometer (Thermo Fisher Scientific).
Whole exome sequencing with 150-bp paired reads was
performed with a NextSeq 500 (Illumina), using 1 lg genomic DNA
and enrichment for whole exome according to SeqCap EZ
MedExome (Roche).
Sequence alignment and variant annotation
Adapters were clipped using Scythe (https://github.com/vsbuffalo/
scythe) and 30 ends with a quality score < 20 over a window of 10
bases were trimmed using Sickle (Joshi & Fass, 2011), entirely
removing the fragment if the final length of one of the reads was
lower than 50 bp. Sequencing reads from each sample were aligned
to the human genome (hg38) using Burrows–Wheeler Aligner
(BWA) mem (Li & Durbin, 2010) with default parameters. PCR
duplicates were removed using rmdup of SAMtools (Li et al, 2009).
Only reads uniquely mapping in the targeted regions were consid-
ered and retained for further analysis. Somatic SNVs and small
insertion/deletions (InDels) were identified using Strelka2 (Kim
et al, 2018). Somatic SNVs and InDels were further retained if (i)
supported by at least 10 mutated reads in the tumor, (ii) had allele
frequency ≥ 5%, (iii) supported by less than one mutated reads in
the normal, and (iv) had a reported Empirical Variant Scoring (EVS)
by Strelka2 ≥ 15. ANNOVAR (Wang et al, 2010) was used to anno-
tate nonsilent (nonsynonymous, stopgain, stoploss, frameshift,
nonframeshift, and splicing modifications) somatic mutations in
each tumor.
Microsatellite stability analysis
Microsatellite instability was analyzed with the MSI Analysis System
kit, Version 1.2 (Promega). Samples displaying variation of at least
two markers are considered instable.
Clonal evolution
The clonal structure of each metastasis was inferred with SciClone
(Miller et al, 2014), with default parameters with the exception of
minDepth that was set equal to 75. As input, all the somatic muta-
tions (including the synonymous) were used. Copy number regions
were identified by CopywriteR package (Kuilman et al, 2015) in
order to exclude from the analysis SNVs falling in copy number
altered regions of the genome. Phylogeny of each metastasis was
inferred using the ClonEvol R package (Dang et al, 2017) with
default parameters using as input the cluster of mutations identified
by SciClone.
Phylogenetic tree reconstruction among metastasis
Phylip (Felsenstein, 2005) (maximum likelihood-based method) was
used to reconstruct the phylogeny among the multiple metastases of
the patient with CUP. As input, we used the same mutations previ-
ously considered for SciClone. The trees in Newick format produced
by Phylip were finally rendered using the R package APE (Paradis
et al, 2004).
Data availability
WES and RNA-seq data have been deposited in the EGA (European
Genome-Phenome Archive) with the accession number EGA
S00001004059 (https://ega-archive.org/studies/EGAS00001004059).
Expanded View for this article is available online.
Acknowledgements
We thank V. Nigro and D. Cacchiarelli for discussing the bioinformatic
data; E. Berrino and T. Venesio for MSS analysis; I. Sarotto for
Immunohistochemical tests; L. Casorzo and M. Panero for FISH tests; and
A. Balsamo for clinical data management. The invaluable secretarial help
of A. Cignetto is acknowledged. The results on the expression profiles are
in part based upon data generated by the TCGA Research Network:
https://www.cancer.gov/tcga. The research leading to these results has
received funding from FONDAZIONE AIRC under 5 per Mille 2018—ID.
21052 program—PI: P. Comoglio; GLs: C. Boccaccio, F. Montemurro, and A.
Sapino; Italian Ministry of Health Ricerca Corrente 2019; and FPRC
5xmille 2014 Ministero Salute. GG was supported by the STAR (Sostegno
Territoriale alle Attività di Ricerca) Grant of University of Naples
Federico II.
The paper explained
Problem
Cancer of unknown primary is an obscure disease characterized by
multiple metastases in the absence of a clinically detectable primary
tumor. The elusive CUP biology results in the lack of pathogenesis-
based therapy.
Results
Fifteen synchronous metastases from a single CUP patient were
analyzed by whole exome and RNA sequencing and their phylogenetic
tree was reconstructed. Surprisingly, a high percentage of mutations,
including those in putative driver genes, were fully shared. Additional
mutations accumulated one after the other in a series, and a few
private mutations were unique to each metastasis. The phylogenetic
trajectory linking CUP metastases depicted an evolution pattern remi-
niscent of a galaxy: a common “stream” sprouting a series of linear
“brooks”.
Impact
The distinctive genetic and evolutionary features of CUPs suggest a
biology different from metastases of cancers of known origin. On the
clinical ground, the unexpected genetic similarity among different
CUP metastases leaves room for a therapeutic strategy aimed at the
simultaneous eradication of multiple lesions.
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